Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

U 89678

Known as: U-89678 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pregnatrienes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Induction of tirilazad clearance by phenytoin
Tirilazad is a membrane lipid peroxidation inhibitor being studied for the management of subarachnoid hemorrhage; phenytoin is… 
1998
1998
Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
The effect of oral finasteride, an inhibitor of 5alpha-reductase, on the clearance of tirilazad, a membrane lipid peroxidation… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
1998
1998
Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.
Tirilazad mesylate (FREEDOX), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the… 
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
1997
1997
Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.
The pharmacokinetics of tirilazad and U-89678 (an active metabolite) were evaluated in 55 adults (48 males, 7 females) with… 
Highly Cited
1996
Highly Cited
1996
Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.
The 21-aminosteroid lipid-peroxidation inhibitor, tirilazad mesylate (U-74006F), recently was shown in a large multinational… 
  • figure 1
  • figure 2
  • figure 3
1996
1996
Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.
The effect of ketoconazole, a CYP3A inhibitor, on the oral bioavailability of tirilazad mesylate was assessed in 12 healthy… 
1996
1996
Pharmacokinetics of Tirilazad and U‐89678 in Ischemic Stroke Patients Receiving a Loading Regimen and Maintenance Regimen of 10 mg/kg/day of Tirilazad
The pharmacokinetics of tirilazad mesylate and its active reduced metabolite, U‐89678, were evaluated in ischemic stroke patients… 
1996
1996
Gender does not affect the degree of induction of tirilazad clearance by phenobarbital
Abstract.Objective: Tirilazad mesylate is a membrane lipid peroxidation inhibitor being evaluated for the treatment of patients… 
  • figure 1
  • table 1
  • figure 2
  • table 2
1995
1995
Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects.
The pharmacokinetics of tirilazad were assessed in men ages 40--60 years, women <40 years of age, premenopausal women ages 40--60… 
1994
1994
The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers
The pharmacokinetic interaction between phenytoin and tirilazad was studied in 12 healthy men who received 200 mg phenytoin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE